The Asia Pacific Consortium on Osteoporosis (APCO), comprising 39 clinical experts from 19 countries and regions across Asia Pacific (APAC), and its proposed ‘Framework’ aims to drive, and facilitate benchmarking for the provision of quality osteoporosis care across the region. According to a co-authored APCO member and Chair viewpoint article published on Monday, June 22,…

Read More

A series of reports released today by MTPConnect, an independent, industry-led organisation, highlight the key role the MedTech sector played in the COVID-19 pandemic response. The reports, welcomed by the Medical Technology Association of Australia (MTAA), reveal how the MedTech, biotechnology and pharmaceutical sector was impacted by COVID-19 at local and multinational levels, as well…

Read More

Yesterday, VIVA! partnered with Celgene, a Bristol-Myers Squibb company and Myeloma Australia to announce the listing of REVLIMID® (lenalidomide) in combination with bortezomib (Velcade) and dexamethasone (RVd) on the Pharmaceutical Benefits Scheme (PBS). Australians living with the incurable blood cancer, multiple myeloma now have access to this new treatment option. The three drug regimen will…

Read More

This week, VIVA! Communications’ Principal and owner, Kirsten Bruce, Sydney spoke with internationally renowned Infectious Diseases Paediatrician and Immunisation expert, Professor Robert Booy, Sydney. They discussed the impact of COVID-19 on Australians to date, its potential implications moving forward, and the barriers facing scientists in their race to develop a vaccine. The rapid and effective…

Read More

How to avoid faux pas & respect your fellow zoomies Working from home presents unique challenges and opportunities for those fortunate enough to be able to do so. Businesses and their employees are doing their best to navigate these unprecedented times, so it’s important to practice patience and respect. Here at VIVA! we are doing…

Read More